Combined, the decreased cardiac expressions of Pdk4 and Ucp3, reduced cardiac glycogen content, and reversion of diabetic cardiomyopathy in O304-treated STZ mice provide evidence that O304 restores cardiac metabolic flexibility and glucose oxidation, i.e., cardiac efficiency, in these mice. Here, PDK4 is linked to diabetic cardiomyopathy.